Short answer
Prime Medicine, Inc. (PRME) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Preliminary liquidity of $61.2 million in cash, equivalents and short-term investments as of September 30, 2026.
Prime Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary liquidity of $61.2 million in cash, equivalents and short-term investments as of September 30, 2026
- Restricted cash adds approximately $13.7 million, but is unavailable for general operating use
- Cash estimate signals limited funding capacity for ongoing operations and clinical development
- Unaudited figures remain subject to quarter-end adjustments and potential material changes
- Complete third-quarter results expected in the Form 10-Q for the quarter ended September 30, 2026
Item 8.01 · Other Events
- Updated corporate presentation posted November 10, 2026, providing investors with the company’s latest strategy and program materials
- Exhibit 99.1 contains the substantive presentation, requiring review for pipeline, clinical, financial, and corporate updates
Item EX-99.1 · Exhibit EX-99.1
- Prime Medicine targets Phase 1/2 initial data for PM577a Wilson disease and PM647 AATD programs in 2027
- PM359 CGD program advancing toward BLA submission in the first half of 2027, pending final FDA alignment
- PM577a focuses on H1069Q Wilson disease mutation, with follow-on programs potentially addressing R778L and other mutations
- PM647 targets PiZZ AATD, with potential to restore healthy AAT protein levels through a one-time treatment
- BMS collaboration provides $110 million upfront, more than $3.5 billion potential milestones and royalties on net sales
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Prime Medicine, Inc. 8-K filings
Get the next PRME 8-K as it lands
Follow PRME for push alerts, or ask the research agent what this filing means.